To assess the presence of perfusion abnormalities in the deep gray matter of patients with relapsingremitting and primary progressive multiple sclerosis (MS) in comparison with healthy controls and to investigate the impact of perfusion impairment on clinical disability and fatigue.
C
ORTICAL AND SUBCORTIcal gray matter (GM) injury is gaining increasing recognition as a prominent pathological substrate of irreversible disability in multiple sclerosis (MS). 1 Several histological and magnetic resonance imaging (MRI) studies have shown that axons and neurons are affected by the disease and that the damage extends beyond the classic lesions into normal-appearing white matter and GM. [2] [3] [4] [5] [6] [7] Despite this evidence, there is still much to learn about the molecular, cellular, and vascular mechanisms leading to GM injury.
Although an ischemic mechanism has long been acknowledged in histological studies of MS, [8] [9] [10] [11] it is only recently that advances in MRI techniques have allowed for investigations of this phenomenon. [12] [13] [14] [15] Inflammation may result in microvascular damage by different mechanisms. Cytotoxic T cells may recognize their antigen on endothelial cells and activate a clotting cascade, which, in turn, leads to thrombosis. Likewise, specific antibodies may recognize their antigen at the vessel wall and induce vascular damage by complement activation. Furthermore, inflammatory edema may impair microcirculation through focal tissue swelling, 16 whereas exudation of inflammatory cells and intravascular fibrin deposition may induce acute and chronic venous obliterations. 17 In addition, obliterative vasculitis might result in chronic ischemia through the modulation of vascular tone and cerebral blood flow. It is possible, therefore, that perfusion abnormalities contribute to neuroaxonal degeneration, which, in turn, leads to disability.
The assessment of cerebral hemodynamics has been made possible through MRI by using dynamic susceptibility contrast-enhanced (DSC) T2*-weighted MRI. 18 This technique uses signal changes that accompany a tracer passing through the cerebral vasculature, which enable a quantitative estimation of cerebral blood flow. Dynamic susceptibility contrast-enhanced perfusion MRI has been applied to the study of several neurological diseases, such as stroke, neoplasm, Alzheimer disease, and MS, to demonstrate perfusion impairment in both lesional and structurally intact brain regions. 19 Unlike the cortex, deep gray nuclei are technically easier to study with this technique because the quantification of tissue perfusion is less affected by the contamination of blood in adjacent large veins. In addition to the presence of lesions, metabolic and structural abnormalities of deep gray nuclei have recently been shown in studies using quantitative MRI techniques. [20] [21] [22] [23] Since the thalami and basal ganglia (BG) are also critical links of cortical-subcortical circuits controlling several neurological domains, their injury or dysfunction may lead to sensorimotor, cerebellar, and cognitive deficits as well as fatigue. The latter has been reported to occur in 78% to 87% of patients with MS, and it has been related to the involvement of subcortical GM. 24, 25 We hypothesized that decreased perfusion in deep GM would reflect neuronal/axonal dysfunction and therefore would be related to neurological deficits and fatigue. We also questioned whether tissue perfusion changes would be more severe in patients with primary progressive (PP) MS than in those with relapsingremitting (RR) MS because of the predominant neurodegeneration in the former. To this end, we used DSC perfusion MRI at 3 T to determine the presence and extent of perfusion abnormalities in the deep GM of patients with MS in comparison with healthy controls. We also investigated the functional correlates of clinical disability and MS-related fatigue.
METHODS

SUBJECTS
Twenty-two patients with MS meeting the McDonald criteria 26 were prospectively enrolled in the study. Eleven patients (3 male and 8 female) had an RR course and 11 patients (7 male and 4 female) had a PP course. Disability was assessed by a single experienced neurologist blind to the MRI findings using the Expanded Disability Status Scale (EDSS) score 27 within 1 week of MRI. Fatigue was assessed by a psychologist blind to the MRI findings using the Multidimensional Fatigue Inventory (MFI), 28 which consists of a 20-item self-report measure assessing 5 dimensions of fatigue: general fatigue, physical fatigue, reduced activity, reduced motivation, and mental fatigue. Each subscale is the sum of 5 items, which are rated on a 5-point scale ranging from 1 (no, not true) to 5 (yes, that is true). Half of the items in the questionnaire are reverse scored to prevent response pattern bias. Subscale scores range from 4 to 20, with lower scores indicating a higher level of fatigue. In addition to MFI, the patients were also assessed with the depression subscale of the Brief Symptom Inventory (BSI). 29 This scale assesses clinical indications of depression such as dysphoric mood and affect as well as reduced motivation and a loss of interest. T scores of 63 or greater indicate a clinically significant level of depression that is equal to the 91st percentile or higher. The mean (SD) values of each of the 5 scores of the MFI and the depression subscale of the BSI are compiled for each group of subjects in 
MRI ACQUISITION
Magnetic resonance imaging was performed using a 3-T scanner (Trio; Siemens Medical Systems, Erlangen, Germany) with an 8-channel phased-array head coil. The following sequences were collected in all subjects during a single MRI session: (1) dual-echo turbo spin echo (repetition time [TR]=5500 milliseconds; echo time [TE]=12/99 milliseconds; 96 contiguous, 3-mm-thick axial slices with a 256 ϫ 205 matrix and a 220 mmϫ190 mm field of view [FOV] ; in-plane voxel size, 0.85 mmϫ0.92 mm; parallel imaging acceleration factor of 2); (2) gradient-echo echo-planar imaging (TR = 1000 milliseconds; TE=32 milliseconds; 10 contiguous, 3-mm-thick axial slices with a 128ϫ128 matrix; 220 mmϫ220 mm FOV; flip angle, 30°; signal bandwidth, 1396 Hz/pixel; in-plane voxel size, 1.7 mmϫ1.7 mm). Dynamic susceptibility contrast-enhanced MRIs were acquired during the first pass of a standard-dose (0.1 mmol/ kg) bolus of gadopentetate dimeglumine (Magnevist; Berlex Laboratories, Wayne, NJ). Contrast was injected at a rate of 5 mL/s, followed by a 20-mL bolus of saline also at a rate of 5 mL/s. A total of 60 images were acquired at 1-second intervals, with the injection occurring at the fifth image so that the 
IMAGE PROCESSING AND EVALUATION
Data were transferred to a Linux workstation for offline perfusion analysis using programs developed in-house using the IDL (interactive data language) programming languages. In all cases, contrast agent concentration, C, is first found using the simple relationship
where S is the signal intensity and S 0 is the prebolus signal intensity averaged between acquisitions 2 and 11. This equation assumes that T1 shortening effects are negligible, which is true in practice since we use a relatively low flip angle to minimize saturation. Absolute cerebral blood volume (CBV), cerebral blood flow (CBF) (Figure 1) , and mean transit time (MTT) were calculated using the method of Rempp et al. 31 These parameters can be calculated from the following equations:
where C is the tissue concentration following an ideal, instantaneous bolus and C max is the maximum value of C. The bolus is not instantaneous, of course, but an approximation to the idealized response can be found by deconvolving the measured tissue concentration with the arterial input function (AIF). Deconvolution of the measured value of C by the AIF was performed by standard Fourier methods. Before deconvolution, gamma variate functions were fitted to both measured curves (C and AIF) to reduce noise and to correct for any leakage due to blood-brain barrier disruption (although in this study we expected little or no contrast extravasation). The AIF was found using an automated method similar to that described by Rempp et al 31 and Carroll et al. 32 The minimum signal, corresponding to the bolus peak, is found in each pixel within the head. The average signal drop and average bolus arrival time are then calculated for all pixels. Pixels where the bolus arrives early and where the signal drop is larger than average are assumed to be within arteries. The AIF was calculated by averaging the signals from the 10 pixels in the scanned region that met these 2 criteria and demonstrated the largest signal drop.
Mean transit time, CBV, and CBF were calculated in regions of interest (ROIs) in the following brain regions: the thalamus, putamen, and the head of the caudate. To optimize reproducibility, CBF, CBV, and MTT measurements were taken in 2 ROIs in each of the 3 regions. Regions of interest were fixed in size (radius of 1 image pixel, 1.7 mm) and were placed to avoid arterial and venous structures. Regions of interest were placed in the same section positions in patients and controls. Within these section positions, ROIs were placed in the same locations within the 3 brain regions described earlier. Perfusion measurements were obtained by 2 of us (M.I. and S.P.) with more than 5 years of experience with this type of measurement in clinical and research settings. To exclude interobserver and minimize intraobserver variability as to the location of ROI placement between patients, each patient data set was reviewed by both of us at the same time, as described elsewhere. 33 Since all MRI sequences were centered to the same position, regardless of the number of slices, the ROIs were placed on the axial gradient-echo echo-planar image using the corresponding transverse T2-weighted image as reference to avoid the inclusion of lesions.
LESION VOLUME MEASUREMENTS
T2-hyperintense and T1-hypointense lesion volume measurements were performed by a single trained technician, blinded to subject identity, using a semiautomated segmentation technique based on local thresholding ( Jim version 3; Xinapse Systems, Northants, England, http://www.xinapse.com), as described elsewhere.
34
STATISTICAL ANALYSIS
Mixed-model regression was used to evaluate differences among subject groups in terms of each perfusion measure and in terms of each of the 5 scores of the MFI scale while adjusting for the 
sides of the given region constituting the dependent variable. The regression model included patient age and sex as covariates and subject group and side of measurement as fixed classification factors. The covariance structure was modeled by assuming observations to be correlated or independent when derived for the same subject or different subjects, respectively, and by allowing the error variance to differ across subject groups. In patients with MS, the mixed-model analysis was also used to examine the association of each perfusion measure with EDSS score, MFI score, T2-weighted and T1-weighted lesion volume, and disease duration. A regression analysis was performed to compare subject groups with respect to the average of each perfusion measure over the 3 regions. Within the mixedmodel format, the Tukey Honestly Significant Difference procedure was used to make all pairwise comparisons among subject groups with respect to each perfusion measure while adjusting for age and sex and maintaining the familywise type I error rate for the set of comparisons at or lower than the 5% level. Results associated with a P value between .10 and .05 are reported as statistical trends since they may correspond to real differences or effects that the study was not adequately powered to detect and therefore are worthy of further investigation. All statistical computations were carried out using SAS for Windows version 9.0 (SAS Institute, Cary, NC).
RESULTS
None of the healthy controls showed lesions on T2-weighted and T1-weighted scans. Median T2 lesion volume was 2.83 mL (range, 0.12-27.9 mL) in patients with RR MS and 3.89 mL (range, 0.39-32.91 mL) in patients with PP MS. Median T1 lesion volume was 0.4 mL (range, 0.04-3.20 mL) in patients with RR MS and 0.36 mL (range, 0.04-21.5 mL) in patients with PP MS. Four patients with RR MS and 4 patients with PP MS had deep GM lesions noted on T2-weighted imaging (all patients with RR MS and 2 patients with PP MS had 1 lesion, whereas 1 patient with PP MS had 3 and 1 had 2 lesions). Although 3 patients with RR MS and 3 patients with PP MS had a BSI score of 63 or higher, the difference between patients and controls was not significant (P=.06). However, since there was a trend toward patients having a higher mean level of depression and since depression is known to influence fatigue, BSI score was accounted for as a covariate in analyses to compare patients and controls in terms of fatigue. After adjustment for age and sex and BSI score, scores for MFI general fatigue (P = .02), physical fatigue (P = .03), reduced activity (P=.009), reduced motivation (P=.01), and mental fatigue (P=.01) were significantly lower in patients with MS compared with healthy controls. The 2 groups of patients were different only in terms of MFI reduced motivation score, which was significantly lower in patients with PP MS than in those with RR MS (P=.05).
COMPARISON OF PERFUSION METRICS BETWEEN PATIENTS WITH PP MS AND RR MS AND CONTROLS
After adjustment for age and sex, significant differences were found between the patients with PP MS and the controls with respect to the CBF (PՅ.004) and CBV (PՅ.009) (Figure 2 ). There were no significant differences among the 3 groups of subjects in terms of MTT (PϾ.30 for all comparisons). Results pertaining to group comparisons with respect to average CBF, CBV, and MTT are given in Table 2 .
CORRELATIONS BETWEEN PERFUSION METRICS, LESION VOLUMES, DISEASE DURATION, EDSS SCORE, AND MFI SCORE
Neither T2 and T1 lesion volumes nor disease duration correlated with the perfusion metrics from the 3 brain regions. A statistical trend was found when investigating the association between the EDSS score and deep GM CBF value (r=−0.27; P=.09) and CBV value (r=−0.28; P=.09). After adjustment for BSI score, the MFI reduced motivation score was significantly correlated with CBF (r=0.4; PϽ.001) and CBV (r=0.5; P=.004) (Figure 3) . In addition, the MFI reduced activity score was significantly correlated with CBF (r=0.4; P=.004). There was no significant correlation between MTT and disease duration, EDSS score, MFI score, or either measure of lesion volume.
COMMENT
Dynamic susceptibility contrast-enhanced perfusion MRI performed at a field strength of 3 T provides several advantages relative to that performed at 1.5 T. 35 At 3 T, the intrinsic signal-to-noise ratio is higher and sensitivity to T2* changes due to contrast agent is increased. This can be traded off for either lower-contrast dose or a shorter TE and, hence, a larger number of slices and improved coverage within a fixed TR. 35 Our observation of reduced CBF and CBV in the deep GM of patients with MS is consistent with several histological and MRI studies suggesting that macroscopic and microscopic structural damage as well as metabolic dysfunction occur in the thalami and BG of patients with (REPRINTED) MS. [20] [21] [22] [23] Several direct and indirect mechanisms might have contributed to the deep GM hemodynamic impairment. First of all, MS lesions are frequently found in the thalamus and BG at postmortem examination. However, lesions are often missed on T2-weighted images because of their small size and poor contrast with the surrounding GM. In addition, diminished blood supply has been described in MS plaques. 13, 36 Although macroscopic deep GM lesions were detected in a few of our patients, theoretically, small deep GM lesions, not detected on MRI, could have contributed to the decrease of perfusion. Second, axonal transection in active white matter lesions could lead indirectly to anterograde and retrograde degeneration of axons running within the thalamus. Finally, neuronal loss itself secondary to hypoperfusion, iron deposition, demyelination, or Wallerian degeneration might contribute to CBF decrease via reduction in local metabolic activity.
Patients with PP MS exhibited a more severe CBF and CBV decrease, consistent with the prominent axonal loss described in this subgroup of patients. This suggests that perfusion metrics are a potential marker of neuroaxonal damage. Admittedly, unlike the patients with PP MS, the patients with RR MS were all undergoing treatment with disease-modifying drugs that may have partially contributed to the lesser degree of hemodynamic impairment. Nonetheless, our findings are consistent with those of a previous study reporting hypoperfusion of cortical and subcortical GM especially in patients with PP and sec- ondary progressive MS. 15 Longitudinal studies in patients in the earliest stages of the disease, coupling perfusion imaging with the assessment of the Nacetylaspartate level, a marker of neuroaxonal viability and integrity, will have to determine whether perfusion impairment is just a marker of neuroaxonal damage and/or a mediator of neurodegeneration.
The main finding of our study is the association between the fatigue score and the impairment of both CBF and CBV in the thalami and BG. This correlation was significant after correcting for the depression subscore of the BSI scale, suggesting that it is unlikely that fatigue might be attributed to the mood status of our patients. Fatigue is defined as a subjective lack of physical and mental energy interfering with usual activities. It is a very frequent complaint in patients with MS and has been shown to be an independent predictor of impaired quality of life. 24, 37 Although the pathophysiology of fatigue has not been elucidated yet, disruption of cortico-subcortical circuits linking the cortex with the deep GM has been proposed as a potential mechanism. 25 Using positron emission tomography, Roelcke et al 38 reported an association between fatigue and the decreased glucose metabolism in the BG and frontal cortex of patients with MS. Similarly, in a functional MRI study, Filippi et al 39 demonstrated that patients with fatigue had reduced activation of cortical areas and the thalamus during a simple motor task. Although frontal GM perfusion was not evaluated in the present study, Rashid et al, 15 using arterial spin labeling, observed hypoperfusion in several cortical areas of patients with relapsing and progressing MS. We speculate, therefore, that the decrease of CBF and CBV in the deep GM may contribute to the dysfunction of brain cortical-subcortical circuits, which in turn results in the onset of fatigue. Conversely, the correlation between physical disability as measured by the EDSS score and CBF and CBV decrease was not significant, although there was a trend toward a negative effect of hypoperfusion on disability. It may be possible that a larger sample size would have yielded a better correlation. However, EDSS measurements are rough estimates of clinical status and are weighted toward locomotor disability, which is likely to depend on spinal cord damage. 27 Neither CBF nor CBV values correlate with disease duration, suggesting that GM dysfunction may occur at any time in deep GM and not only in the later stage of the disease. Likewise, no association was found between T2 or T1 lesion volumes and perfusion parameters, suggesting that, at least in our patients, the hemodynamic changes of deep GM cannot be explained by the indirect effects of white matter lesions. As mentioned earlier, not only is the deep GM not spared by MS, but its estimated number of lesions per gram wet weight is higher than any other brain structure. 40 There are important limitations to our study to be considered. The small sample size and concomitant low statistical power may, at least partly, explain certain nonsignificant findings such as the lack of association of EDSS score and lesion loads with perfusion measures. We are aware, therefore, that, owing to their preliminary nature, the interpretation of these findings has to be cautious. In addition, the RR MS group was undergoing treatment with immunomodulatory treatments whose impact on vascular permeability and inflammation is unknown. We are in the process of obtaining data in patients before and after immunomodulating therapy to assess for a possible effect of treatment on perfusion parameters.
